INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4201, 6221, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4202, 7329, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4203, 7330, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4204, 12965, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4205, 13118, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4206, 13322, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4207, 14745, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4208, 14747, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4209, 14748, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4210, 14879, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4211, 17141, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4212, 17142, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4213, 21121, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4214, 21122, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4215, 21848, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4216, 21849, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4217, 21850, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4218, 21851, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4219, 24390, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4220, 24391, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4221, 25918, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4222, 29354, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4223, 29606, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4224, 29607, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4225, 29608, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4226, 30068, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4227, 32064, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4228, 32789, 'Linezolid', 'Kidney Diseases', 'Linezolid is primarily metabolized by the liver and subsequently eliminated by the kidney.  The pharmacokinetics of the parent drug are not altered in patients with impaired renal function and, therefore, no dosage adjustments are necessary.  However, accumulation of the two primary metabolites may occur in such patients, the amount of which increases with the degree of renal impairment.  The clinical significance of metabolite accumulation has not been determined.  Therapy with linezolid should be administered cautiously in patients with renal impairment and only if benefits outweigh the potential risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4229, 1162, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4230, 6221, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4231, 7329, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4232, 7330, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4233, 12965, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4234, 13118, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4235, 13322, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4236, 14745, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4237, 14747, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4238, 14748, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4239, 14879, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4240, 17141, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4241, 17142, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4242, 21121, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4243, 21122, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4244, 21848, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4245, 21849, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4246, 21850, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4247, 21851, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4248, 24390, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4249, 24391, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4250, 25918, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4251, 29354, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4252, 29606, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4253, 29607, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4254, 29608, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4255, 30068, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4256, 32064, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4257, 32789, 'Linezolid', 'Seizures', 'Caution is recommended when prescribing linezolid to patients with a history of seizures or risk factors for seizures as convulsions have been reported with the use of this agent.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4258, 8332, 'Apomorphine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4259, 22989, 'Apomorphine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4260, 23054, 'Apomorphine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4261, 8332, 'Apomorphine', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4262, 22989, 'Apomorphine', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4263, 23054, 'Apomorphine', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4264, 17400, 'Lofexidine', 'Hypotension', 'Lofexidine can cause a decrease in blood pressure, a decrease in pulse, and syncope.  It is recommended to monitor vital signs before dosing and for symptoms related to bradycardia and orthostasis.  If clinically significant or symptomatic hypotension and/or bradycardia occur, the next dose of lofexidine should be reduced in amount, delayed, or skipped.  Avoid using lofexidine in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, chronic renal failure, and in patients with marked bradycardia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4265, 17400, 'Lofexidine', 'Alcoholism', 'Lofexidine can potentiate the CNS depressive effects of alcohol and other CNS depressive substances.  Care should be exercised when using this agent in patients with alcohol disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4266, 17400, 'Lofexidine', 'Hepatic Insufficiency', 'Hepatic impairment slows the elimination of lofexidine, but exhibits less effect on the peak plasma concentration following a single dose.  Dosage adjustments are recommended based on the degree of hepatic impairment.  Close monitoring is recommended when using this agent in patients with hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4267, 17400, 'Lofexidine', 'Long QT Syndrome', 'Lofexidine prolongs the QT interval.  Its use should be avoided in patients with congenital long QT syndrome.  It is recommended to monitor ECG prior to and during treatment in patients with congestive heart failure, bradyarrhythmias, hepatic impairment, renal impairment, or patients taking other medicinal products that lead to QT prolongation (e.g., methadone).  Electrolyte abnormalities must be corrected prior to initiating therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4268, 17400, 'Lofexidine', 'Kidney Diseases', 'Renal impairment slows the elimination of lofexidine but exhibits less effect on the peak plasma concentration than on AUC values following a single dose.  Dosage adjustments are recommended based on the degree of renal impairment.  Only a negligible fraction of the lofexidine dose is removed during a typical dialysis session, so no additional dose needs to be administered after a dialysis session; therefore, the agent may be administered without regard to the timing of dialysis.  Close monitoring is recommended when using this agent in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4269, 5593, 'Acarbose', 'Fibrosis', 'The use of acarbose is contraindicated in patients with primary cirrhosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4270, 24143, 'Acarbose', 'Fibrosis', 'The use of acarbose is contraindicated in patients with primary cirrhosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4271, 5593, 'Acarbose', 'Kidney Diseases', 'Acarbose may accumulate in patients with renal impairment.  Following oral administration, 35% of a dose is recovered in the urine as either the parent drug or metabolites.  However, long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine > 2.0 mg/dL) have not been conducted.  Therapy with acarbose should be administered cautiously in patients with renal dysfunction.  The manufacturer does not recommend its use in patients with significantly impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4272, 24143, 'Acarbose', 'Kidney Diseases', 'Acarbose may accumulate in patients with renal impairment.  Following oral administration, 35% of a dose is recovered in the urine as either the parent drug or metabolites.  However, long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine > 2.0 mg/dL) have not been conducted.  Therapy with acarbose should be administered cautiously in patients with renal dysfunction.  The manufacturer does not recommend its use in patients with significantly impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4273, 5593, 'Acarbose', 'Diabetic Ketoacidosis', 'The use of alpha-glucosidase inhibitors is contraindicated for the treatment of patients with diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4274, 24143, 'Acarbose', 'Diabetic Ketoacidosis', 'The use of alpha-glucosidase inhibitors is contraindicated for the treatment of patients with diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4275, 5593, 'Acarbose', 'Intestinal Diseases', 'The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption.  Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates.  Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4276, 24143, 'Acarbose', 'Intestinal Diseases', 'The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption.  Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates.  Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4277, 5593, 'Acarbose', 'Liver Diseases', 'The use of acarbose has been associated with dose-related elevations in serum transaminase levels and, rarely, hyperbilirubinemia and jaundice.  Hepatic adverse effects may be more likely to occur at dosages exceeding 50 mg three times a day.  Therapy with acarbose should be administered cautiously in patients with liver disease.  Monitoring of serum transaminases is recommended every 3 months during the first year of treatment and periodically thereafter.  If hepatotoxicity is suspected at any time, a dosage reduction or withdrawal of therapy may be indicated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4278, 24143, 'Acarbose', 'Liver Diseases', 'The use of acarbose has been associated with dose-related elevations in serum transaminase levels and, rarely, hyperbilirubinemia and jaundice.  Hepatic adverse effects may be more likely to occur at dosages exceeding 50 mg three times a day.  Therapy with acarbose should be administered cautiously in patients with liver disease.  Monitoring of serum transaminases is recommended every 3 months during the first year of treatment and periodically thereafter.  If hepatotoxicity is suspected at any time, a dosage reduction or withdrawal of therapy may be indicated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4279, 616, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4280, 617, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4281, 618, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4282, 3133, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4283, 3134, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4284, 6776, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4285, 6777, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4286, 7547, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4287, 7553, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4288, 21241, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4289, 22049, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4290, 22050, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4291, 22054, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4292, 22056, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4293, 22057, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4294, 22064, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4295, 22065, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4296, 22066, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4297, 22084, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4298, 22085, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4299, 25862, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4300, 26503, 'Losartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
